«Our findings suggest further investigation into the potential of MC1R - activating agents as novel neuroprotective therapies for PD, and together with
epidemiological evidence, may offer
information that could guide those carrying MC1R variants to seek advice from dermatologists or neurologists
about their personal risk for melanoma and Parkinson's disease,» lead author Xiqun Chen says in a statement.